Literature DB >> 16964333

Molecular epidemiology of drug-resistant Salmonella Typhimurium in Spain.

N Delgado Ronda1, J L Muñoz Bellido, M I García García, R Ibáñez Pérez, S Muñoz Criado, R Serrano Heranz, M C Sáenz González, J A García Rodríguez.   

Abstract

One hundred and forty-seven Salmonella serotype Typhimurium strains isolated in three provinces in the midwest of Spain were studied. Of these, 93.6% were drug resistant. There were two predominant resistance phenotypes: 43 isolates (29.3%) were resistant to amoxicillin, tetracyclines, chloramphenicol, streptomycin and sulphamethoxazole and 27 isolates (18.4%) to amoxicillin, amoxicillin/clavulanic acid, tetracyclines, chloramphenicol, streptomycin and sulphamethoxazole. Randomly amplified polymorphic DNA (RAPD) analysis and pulsed field gel electrophoresis (PFGE) were performed for molecular typing. Thirty-six DNA band profiles were differentiated by RAPD, and 38 by PFGE. We found a high level of clonality; 27% of strains were identical by both methods. There were additional smaller clonal lines within every area. The highest discriminatory power was obtained with PFGE, but the greatest degree of genetic diversity was observed among Salmonella Typhimurium using both RAPD and PFGE.

Entities:  

Mesh:

Year:  2006        PMID: 16964333

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  2 in total

1.  Salmonella enterica serotype 4,5,12:i:-, an emerging Salmonella serotype that represents multiple distinct clones.

Authors:  Y Soyer; A Moreno Switt; M A Davis; J Maurer; P L McDonough; D J Schoonmaker-Bopp; N B Dumas; T Root; L D Warnick; Y T Gröhn; M Wiedmann
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

2.  Typing of Salmonella Typhi strains isolated from Egypt by RAPD PCR.

Authors:  Noha A Rezk; Hoda Mansour; Nahed H Ghoneim; Mahmoud M Rifaat
Journal:  3 Biotech       Date:  2011-08-30       Impact factor: 2.406

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.